{
    "clinical_study": {
        "@rank": "154595", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 7", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 3): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 8", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 4/5/6): up to 400 mg GS-5816 QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 9", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 10", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 11", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }, 
            {
                "arm_group_label": "Cohort 12", 
                "arm_group_type": "Experimental", 
                "description": "(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to assess the safety, tolerability, antiviral activity and\n      pharmacokinetics of GS-5816 in HCV treatment na\u00efve subjects with genotypes 1-6."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Administration of GS-5816 will be limited to 3 consecutive days to minimize the potential\n      development of resistance. All subjects will be monitored for up to 48 weeks post-dose to\n      determine the persistence of viral mutations. Twelve cohorts are planned for the\n      examination; within each cohort subjects will receive QD doses of GS-5816 with safety,\n      antiviral activity and pharmacokinetic assessments evaluated at specified time-points during\n      the study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV treatment-na\u00efve adult subjects (18-65 years of age)with chronic HCV infection and\n             plasma HCV RNA \u2265 5 log10 IU/mL at screening\n\n          -  Agree to use protocol defined precautions against pregnancy\n\n        Exclusion Criteria:\n\n          -  Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease,\n             \u03b11 antitrypsin deficiency, cholangitis)\n\n          -  Evidence of cirrhosis\n\n          -  Evidence of current drug abuse\n\n          -  Screening laboratory results outside the protocol specified requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740791", 
            "org_study_id": "GS-US-281-0102"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4", 
                "Cohort 5", 
                "Cohort 6", 
                "Cohort 7", 
                "Cohort 8", 
                "Cohort 9", 
                "Cohort 10", 
                "Cohort 11", 
                "Cohort 12"
            ], 
            "description": "3 days of monotherapy of GS-5816", 
            "intervention_name": "GS-5816", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis C", 
            "HCV", 
            "Genotype 1", 
            "Genotype 2", 
            "Genotype 3", 
            "Genotype 4", 
            "Genotype 5", 
            "Genotype 6", 
            "Liver Disease"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }, 
                    "name": "West Coast Clinical Trials, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Deland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Avail Clinical Research, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }, 
                    "name": "Kansas City Gastroenterology and Hepatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "CRI Worldwide, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }, 
                    "name": "CRI Worldwide, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center for Clinical Research-Knoxville"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Alamo Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98418"
                    }, 
                    "name": "Charles River Clinical Services Northwest, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Fundacion De Investigacion De Diego"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "12", 
        "official_title": "Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "John McNally, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Number of participants with Adverse Events, laboratory abnormalities and ECG abnormalities.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Change from baseline in HCV RNA", 
                "measure": "Antiviral Activity", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximal reduction over time in HCV RNA and proportion of subject with HCV RNA < LLOQ.", 
                "measure": "Viral Dynamics", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Sequence changes in the NS5A coding region of HCV following multiple dose administration of GS-5816 and for up to 48 weeks thereafter", 
                "measure": "Characterization of NSA5a coding region in HCV following dose administration of GS-5816", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Pharmacokinetics parameters will include Cmax, Tmax, AUC, T1/2", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Changes in HCV NS5A sequence following administration of GS-5816", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}